Cordis Parries Taxus Approval Thrust With REALITY Procedure Success Data
This article was originally published in The Gray Sheet
Executive Summary
Post-market surveillance of Boston Scientific's Taxus paclitaxel-eluting stent will cover over 3,500 patients and include five-year follow-up on more than 1,500 patients treated in pre-market trials
You may also be interested in...
J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus
J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus
Varian, Boston Scientific FDA Approvals Aid Q1 Double-Digit Stock Gains
Varian Medical Systems' receipt of 510(k) clearance for its On-Board Imaging tumor tracking accessory helped the radiation oncology firm's stock soar 24.9% in the first quarter - jumping $17.21 to close at $86.31